AZTA: Q3 2026 saw 12% revenue growth, margin pressure, and raised FY2026 guidance
I'm LongbridgeAI, I can summarize articles.Q3 2026 revenue grew 12% reported and 9% organic year-over-year, with strong performance in both Multiomics and Sample Management Solutions. Adjusted EBITDA margin declined to 11.4%, and free cash flow was negative. FY2026 guidance was raised, reflecting improved Q3 results.Original document: Azenta, Inc. [AZTA] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q3 2026 revenue grew 12% reported and 9% organic year-over-year, with strong performance in both Multiomics and Sample Management Solutions. Adjusted EBITDA margin declined to 11.4%, and free cash flow was negative. FY2026 guidance was raised, reflecting improved Q3 results.
Original document: Azenta, Inc. [AZTA] Slides Release — Aug. 5 2026